Essentials of circulating tumor cells for clinical research and practice

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 2, 2013, Pages 338-356

  Liberko, Marian ^a   Kolostova, Katarina ^a   Bobek, Vladimir ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer stem cells; Circulating tumor cells; Clinical significance; Detection methods; Epithelial mesenchymal transition

Indexed keywords

ANTINEOPLASTIC AGENT; CD24 ANTIGEN; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; UVOMORULIN;

BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CELL SIZE; CELL TRANSDIFFERENTIATION; CIRCULATING TUMOR CELL; COLORECTAL CANCER; DENSITY GRADIENT CENTRIFUGATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; ELECTROPHORESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOMAGNETIC SEPARATION; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MICROCHIP ANALYSIS; MICROFLUIDIC ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TUMOR MICROENVIRONMENT; TUMOR SEEDING;

CANCER STEM CELLS; CIRCULATING TUMOR CELLS; CLINICAL SIGNIFICANCE; DETECTION METHODS; EPITHELIAL-MESENCHYMAL TRANSITION;

ANIMALS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PROGNOSIS;

EID: 84885843652     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.05.002     Document Type: Review

References (247)

1. Birchmeier C. Epithelial-mesenchymal transitions in cancer progression. Acta Anatomica (Basel) 1996, 156:217-226.
2. De Wever O., Pauwels P., De Craene B., Sabbah M., Emami S., Redeuilh G., et al. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasive front. Histochemistry and Cell Biology 2008, 130:481-494.
3. Yang J., Weinberg R.A. Epithelial-mesenchymal transitions: at the crossroads of developement and tumor metastasis. Developmental Cell 2008, 14:818-829.
4. Ivatsuki, Mimori K., Yokobori T., Ishi H., Beppu T., Nakamori S., et al. Epithelial-mesenchymal transition in cancer developement and its clinical significance. Cancer Science 2009, 101:293-299.
5. Klymkowski, Savagner P. Epithelial-mesenchymal transition: a cancer research's conceptual friend and foe. American Journal of Pathology 2009, 174:1588-1593.
6. Chambers, Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastic sites. Nature Reviews Cancer 2002, 2:563-572.
7. Eccles S.A., Welch D.R. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007, 369:1742-1757.
8. Fidler I.J. The pathogenesis of cancer metastasis: the seed and soil hypothesis revisited. Nature Reviews Cancer 2003, 3:453-458.
9. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679-695.
10. Shook, Keller R. Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early developement. Mechanisms of Development 2003, 120(11):1351-1383.
11. Schafer M., Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nature Reviews Molecular Cell Biology 2008, 9(8):628-638.
12. Thiery J.P. Epithelial-mesenchymal trasnsitions in tumor progeression. Nature Reviews Cancer 2002, 2:442-454.
13. Maheswaran S., Haber D.A. Circulating tumor cells: a window into cancer biology and metastasis. Current Opinion in Genetics and Development 2010, 20:96-99.
14. Hay Ed. An overview of epithelio-mesenchymal transformation. Acta Anatomica 1995, 154(1):8-20.
15. Thiery J.P. Epithelial-mesenchymal transitions in developent and pathologies. Current Opinion in Cell Biology 2003, 15(6):740-746.
16. Jechlinger, Grunert S., Tamir I.H., Janda E., Lüdemann S., Waerner T., et al. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003, 22:7155-7169.
17. Christofori G. New signalis from the invasive front. Nature 2006, 441:440-450.
18. Perl, Wilgenbus P., Dahl U., Semb H., Christofori G. A casual role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998, 392:190-193.
19. Semb H., Christofori G. The tumor-suppressor function of E-cadherin. American Journal of Human Genetics 1998, 63:1588-1593.
20. Derksen, Liu X., Saridin F., van der Gulden H., Zevenhoven J., Evers B., et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006, 10:437-449.
21. Hulit, Suyama K., Chung S., Keren R., Agiostratidou G., Shan W., et al. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Research 2007, 67:3106-3116.
22. Onder, Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research 2008, 68:3645-3654.
23. Grossmann J. Molecular mechanisms of detachment-induced apoptosis-anoikis. Apoptosis 2002, 7:247-260.
24. Frisch S.M., Francis H. Disruption od epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology 1994, 124:619-626.
25. Kajita M., McClinic K.N., Wade P.A. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol. 2004, 24(17):7559-7566.
26. Vega S., Morales A.V., Ocaña O.H., Valdés F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004, 18(10):1131-1143.
27. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in developement and cancer. Developement 2005, 132:3151-3161.
28. Sayan, Griffiths T.R., Pal R., Browne G.J., Ruddick A., Yagci T., et al. SIP1 protein protects cells from DNA damage-induced apoptosis and has indenpendent prognostic value in blader cancer. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:14884-14889.
29. Scheel, Onder T., Karnoub A., Weinberg R.A. Adaptation versus selection: the origins of metastatic behavior. Cancer Research 2007, 67:11476-11479.
30. Huber, Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Current Opinion in Cell Biology 2005, 17:548-558.
31. Barr, Thomson S., Buck E., Russo S., Petti F., Sujka-Kwok I., et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal transitions. Clinical and Experimental Metastasis 2008, 25:685-693.
32. Moustakas A., Heldin C.H. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007, 98(10):1512-1520.
33. van Hinsbergh, Engelse M.A., Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2006, 26:716-728.
34. Gilles C. Matrix metalloproteases and epithelia-to-mesenchymal transition: implications for carcinoma metastasis 2005, 1-19. Eurekan.com and Kluwer Academic/Plenum Publishers. Rise and Fall of Epithelial Phenotype: concepts of Epithelial-Mesenchymal Transition, Savanger.
35. Huang, Yang W.H., Chang S.Y., Tai S.K., Tzeng C.H., Kao J.Y., et al. Regulation of membrane-type 4,atrix metalloproteinase by SLUG contributes to hypoxia-mediated metastasis. Neoplasia 2009, 11:1317-1382.
36. Ota, Li X.Y., Hu Y., Weiss S.J. Introduction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:20318-20323.
37. Orlichenko L.S., Radisky D.C. Matrix metalloproteinases stimulate epithelial-mesenchymal transition durin tumor developement. Clinical and Experimental Metastasis 2008, 25:593-600.
38. Lo, Hsu S.C., Xia W., Cao X., Shih J.Y., Wei Y., et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of Twist gene expression. Cancer Research 2007, 67:9066-9076.
39. Boyer B., Thiery J.P. Cyclic AMP distinguishes between two functions of acidic FGF in a rat bladder carcinoma cell line. Journal of Cell Biology 1993, 120:767-776.
40. Grotegut, von Schweinitz D., Christofori G., Lehembre F. Hepatocyte growth factore induces cell scattering through MAPK/Egr-1-mediated up-regulation of Snail. EMBO Journal 2006, 25:3534-3545.
41. Peinado, Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumor progression: an alliance against the epithelial phenotype?. Nature Reviews Cancer 2007, 7:415-428.
42. Radisky D.C., Bissel M.J. NF-kappaB links oestrogen receptor signaling and EMT. Nature Cell Biology 2007, 9:361-363.
43. Labelle, Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20(5):576-590.
44. Ogunwobi O.O., Liu C. Therapeutic and prognostic importance of epithelial-mesenchymal transition in liver cancers: insights from experimental models. Critical Reviews in Oncology/Hematology 2012, 83(3):319-328.
45. Gimbrone, Leapman S.B., Cotran R.S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. Journal of Experimental Medicine 1972, 136:261-276.
46. Baish J.W., Jain R.K. Cancer, angiogenesis and fractals. Nature Medicine 1998, 4:984.
47. Sullivan, Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer and Metastasis Reviews 2007, 26:319-331.
48. Yang, Wu M.Z., Chiou S.H., Chen P.M., Chang S.Y., Liu C.J., et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology 2008, 10:295-305.
49. Imai, Horiuchi A., Wang C., Oka K., Ohira S., Nikaido T., et al. Hypoxia attenuates the expression of E-cadherin via upregulation of SNAIL in ovarian carcinoma cells. American Journal of Pathology 2003, 163:1437-1447.
50. Evans, Russell R.C., Roche O., Burry T.N., Fish J.E., Chow V.W., et al. VHL promotes E2 box dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Molecular and Cellular Biology 2007, 27:157-169.
51. Das, Tsuchida R., Malkin D., Koren G., Baruchel S., Yeger H. Hypoxia enhancess tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 2008, 26:1818-1830.
52. Heddleston, Li Z., McLendon R.E., Hjelmeland A.B., Rich J.N. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
53. Peinado, Marin F., Cubillo E., Stark H.J., Fusenig N., Nieto MA, et al. Snail an E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. Journal of Cell Science 2004, 117:827-839.
54. Kuo, Su C.H., Liu C.Y., Chen T.H., Chen C.P., Wang H.S. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435 cells through the up-regulation of membrane type-1 matrix metalloproteinase. International Journal of Cancer 2009, 124:2568-2576.
55. Chabottaux, Ricaud S., Host L., Blacher S., Paye A., Thiry M., et al. Membrane-Type 4 Matrix Metalloproteinase (MT4-MMP) induces lung metastasis by alteration of primary breast tumor vasculature architecture. Journal of Cellular and Molecular Medicine 2009, 13:4002-4013.
56. Peyri, Berard M., Fauvel-Lafeve F., Trochon V., Arbeille B., Lu H., et al. Breast tumor cells transendothelial migration induces endothelial cell anoikis through extracellular matrix degradation. Anticancer Research 2009, 29:2347-2355.
57. Ziegelschmidt, Hollmann C., Gutierrez B., Albert W., Strothoff D., Gross E., et al. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Research 2005, 25:1803-1810.
58. Ziegelschmidt, Hollmann C., Böcher O. Detection of disseminated tumor cells in peripheral blood. Critical Reviews in Clinical Laboratory Sciences 2005, 42:155-196.
59. Pantel K., Otte M. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumor cells. Seminars in Cancer Biology 2001, 11:327-337.
60. Allard, Matera J., Miller M.C., Repollet M., Connelly M.C., Rao C., et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clinical Cancer Research 2004, 10:6897-6904.
61. Demel, Tilz G.P., Foeldes-Papp Z., Gutierrez B., Albert W.H., Böcher O. Detection of tumour cells in the peripheral blood of patients with breast cancer. Development of a new sensitive and specific immunomolecular assay. Journal of Experimental and Clinical Cancer Research 2004, 23(3):465-468.
62. Lankiewicz, Rivero B.G., Bócher O. Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment. Molecular Biotechnology 2006, 34:15-27.
63. Talasaz A.H., Powell A.A., Huber D.E., Berbee J.G., Roh K.H., Yu W., et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009, 106(10):3970-3975.
64. Andreopoulou, Yang L.Y., Rangel K.M., Reuben J.M., Hsu L., Krishnamurthy S., et al. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. International Journal of Cancer 2012, 130(7):1590-1597.
65. Muller, Riethdorf S., Rack B., Janni W., Fasching P.A., Solomayer E., et al. Prognostic impact of circulating tumor cells assessed with the CellSearch Assay™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Research 2012, 14(4):R118. [Epub ahead of print].
66. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer 2009, 9:265-273.
67. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006, 7:131-142.
68. Aktas, Tewes M., Fehm T., Hauch S., Kimmig R., Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Research 2009, 11:R46.
69. Kallergi, Papadaki M.A., Politaki E., Mavroudis D., Georgoulias V., Agelaki S. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Research 2011, 13(3):R59.
70. Mego, Mani S.A., Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nature Reviews Clinical Oncology 2010, 7(12):693-701.
71. Vona, Sabile A., Louha M., Sitruk V., Romana S., Schütze K., et al. Isolation by size of epithelial tumor cells: a new method for immunomorphological and molecular characterisation of circulatin tumor cells. American Journal of Pathology 2000, 156:57-63.
72. Hofman, Long E., Ilie M., Bonnetaud C., Vignaud J.M., Fléjou J.F., et al. Morphological analysis of circulating tumor cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumor cell (ISET) method. Cythopatology 2012, 23(1):30-38.
73. Paterlini-Brechot P., Benali N.L. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Letters 2007, 253:180-204.
74. Hofman, Bonnetaud C., Ilie M.I., Vielh P., Vignaud J.M., Fléjou J.F., et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clinical Cancer Research 2011, 17:827-835.
75. Hofman, Ilie M.I., Long E., Selva E., Bonnetaud C., Molina T., et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch assay™ and the isolation by size of epithelial tumor cell method. Interantional Journal of Cancer 2011, 129:1651-1660.
76. Lecharpentier, Vielh P., Perez-Moreno P., Planchard D., Soria J.C., Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. British Journal of Cancer 2011, 105(9):1338-1341.
77. Krebs, Hou J.M., Sloane R., Lancashire L., Priest L., Nonaka D. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. Journal of Thoracic Oncology 2012, 7(2):306-315.
78. Armstrong, Marengo M.S., Oltean S., Kemeny G., Bitting R.L., Turnbull J.D., et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 2011, 9(8):997-1007.
79. Strauss, Li Z.Y., Liu Y., Beyer I., Persson J., Sova P., et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE 2011, 6(1):e16186.
80. Dessiter, Guerrouahen B.S., Benali-Furet N., Wechsler J., Jänne P.A., Kuang Y., et al. A new device for rapid isolation and characterisation of rare circulating tumor cells. Anticancer Research 2011, 31(2):427-442.
81. Farace, Massard C., Vimond N., Drusch F., Jacques N., Billiot F., et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. British Journal of Cancer 2011, 105(6):847-853.
82. Powell, Talasaz A.H., Zhang H., Coram M.A., Reddy A., Deng G., et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer celllines. PLoS ONE 2012, 7(5):e33788.
83. Mostert, Sleijfer S., Foekens J.A., Gratama J.W. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treatment Reviews 2009, 35:463-474.
84. Balic, Dandachi N., Hofmann G., Samonigg H., Loibner H., Obwaller A. Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry Part B: Clinical Cytometry 2005, 68:25-30.
85. Gertler, Rosenberg R., Fuehrer K., Dahm M., Nekarda H., Siewert J.R. Detection of circulating tumor cells in bloof using an optimized density gradient centrifugation. Recent Results in Cancer Research 2003, 162:149-155.
86. Dickinson, Tsinberg P., Tang Z., Bischoff F.Z., Wilson T., Leonard E.F. Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics 2011, 5(3):34119-341195.
87. Mikolajczyk, Millar L.S., Tsinberg P., Coutts S.M., Zomorrodi M., Pham T., et al. Detection of EpCAM-negatove and cytokeratin-negative circulating tumor cells in peripheral blood. Journal of Oncology 2011, 252361.
88. Pecot, Bischoff F.Z., Mayer J.A., Wong K.L., Pham T., Bottsford-Miller J., et al. A novel platform for detection of CK+ and CK- CTCs. Cancer Discovery 2011, 1(7):580-586.
89. Mayer, Pham T., Wong K.L., Scoggin J., Sales E.V., Clarin T., et al. FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform. Cancer Genetics 2011, 204(11):589-595.
90. Nagrath S., Sequist L.V., Maheswaran S., Bell D.W., Irimia D., Ulkus L., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007, 450(7173):1235-1239.
91. Maheswaran, Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. New England Journal of Medicine 2008, 359:366-377.
92. Stott, Lee R.J., Nagrath S., Yu M., Miyamoto D.T., Ulkus L., et al. Isolation and characterisation of circulating tumor cells from localized and metastatic prostate cancer patients. Science Translational Medicine 2010, 2(25):25ra23.
93. Stott, Hsu C.H., Tsukrov D.I., Yu M., Miyamoto D.T., Waltman B.A., et al. Isolation of circulating tumor cells using a microvortex-generating herringbone chip. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(43):18392-18397.
94. Lin, Zheng S., Williams A.J., Balic M., Groshen S., Scher H.I., et al. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clinical Cancer Research 2010, 16(20):5011-5018.
95. Lin, Balic M., Zheng S., Datar R., Cote R.J. Disseminated and circulating tumor cells: role in effective cancer management. Critical Reviews in Oncology/Hematology 2011, 77(1):1-11.
96. Marrinucci, Bethel K., Kolatkar A., Luttgen M.S., Malchiodi M., Baehring F., et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Physical Biology 2012, 9(1):016003. [Epub 2012 February 3].
97. Kuhn P., Bethel K. A fluid biopsy as investigating technology for the solid phase of solid tumors. Physical Biology 2012, 9(1):010301. [Epub 2012 February 3].
98. Phillips, Kolatkar A., Rees K.J., Rigg R., Marrinucci D., Luttgen M., et al. Quantification of cellular volume and sub-cellular density fluctuations: comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient. Frontiers in Oncology 2012, 2:96.
99. Phillips, Velasco C.R., Li J., Kolatkar A., Luttgen M., Bethel K., et al. Optical quantification of cellular mass, volume, and density of circulating tumor cells identified in an ovarian cancer patient. Frontiers in Oncology 2012, 2:72. [Epub 2012 July 18].
100. Cho, Wendel M., Luttgen M., Yoshioka C., Marrinucci D., Lazar D., et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Physical Biology 2012, 9(1):016001. [Epub 2012 February 3].
101. Zhang, Han L., Cao L., Liang X., Liu Y., Liu H., et al. Aggregation formation mediated anoikis resistance of BEL7402 hepatoma cells. Folia Histochemica et Cytobiologica 2008, 46(3):331-336.
102. Nieva, Wendel M., Luttgen M.S., Marrinucci D., Bazhenova L., Kolatkar A., et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Physical Biology 2012, 9(1):016004.
103. Wendel, Bazhenova L., Boshuizen R., Kolatkar A., Honnatti M., Cho E.H., et al. Fluid biopsy for circulating tumor cell identification in patients with early- and late-stage non-small cell lunf cancer: a glimpse into lung cancer biology. Physical Biology 2012, 9(1):016005. [Epub 2012 February 3].
104. Alix-Panabiéres, Brouillet J.P., Fabbro M., Yssel H., Rousset T., Maudelonde T., et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. Journal of Immunological Methods 2005, 299(1-2):177-188.
105. Alix-Panabiéres, Vendrell J.P., Pellé O., Rebillard X., Riethdorf S., Müller V., et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clinical Chemistry 2007, 53:537-539.
106. Alix-Panabiéres, Vendrell J.P., Slijper M., Pellé O., Barbotte E., Mercier G., et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Research 2009, 11(3):R39.
107. He, Wang H., Hartmann L.C., Cheng J.X., Low P.S. In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(28):11760-11765.
108. Galanzha, Shashkov E.V., Kelly T., Kim J.W., Yang L., Zharov V.P. In vivo magnetic enrichemnt and multiplex photoacoustic detection of circulating tumor cells. Nature Nanotechnology 2009, 4:855-860.
109. Galanzha, Shashkov E.V., Spring P.M., Suen J.Y., Zharov V.P. In vivo, non-invasive, label-free detection and erradication of circulating metastatic melanoma cells using two-color photoacustic flow cytometry with diode laser. Cancer Research 2009, 69(20):7926-7934.
110. Paris, Kobayashi Y., Zhao Q., Zeng W., Sridharan S., Fan T., et al. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Letters 2009, 277:164-173.
111. Lu, Fan T., Zhao Q., Zeng W., Zaslavsky E., Chen J.J., et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. International Journal of Cancer 2010, 126:669-683.
112. Glenhorn, Pratt E.D., Denning D., Liu H., Bander N.H., Tagaea S.T., et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010, 10(1):27-29.
113. Kirby, Jodari M., Loftus M.S., Gakhar G., Pratt E.D., Chanel-Vos C., et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS ONE 2012, 7(4):e35976.
114. Hughes, Mattison J., Western L.T., Powderly J.D., Greene B.T., King M.R. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood. Clinical Chemistry 2012, 58(5):846-853.
115. Hughes, Mattison J., Western L.T., Powderly J.D., Greene B.T., King M.R. Rapid isolation of viable circulating tumor cells from patient blood samples. Journal of Visualized Experiments 2012, (64):e4248.
116. Parkinson, Dracopoli N., Petty B.G., Compton C., Cristofanilli M., Deisseroth A., et al. Considerations in the development of circulating tumor cell technology for clinical use. Journal of Translational Medicine 2012, 10:138.
117. Giordano A., Cristofanilli M. CTCs in metastatic breast cancer. Recent Results in Cancer Research 2012, 195:193-201.
118. Ignatiadis, Rothé F., Chaboteaux C., Durbecq V., Rouas G., Criscitiello C., et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE 2011, 6(1):e15624.
119. Hayes, Walker T.M., Singh B., Vitetta E.S., Uhr J.W., Gross S., et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. International Journal of Oncology 2002, 21(5):1111-1117.
120. Meng, Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(25):9393-9398.
121. Fehm, Becker S., Duerr-Stoerzer S., Sotlar K., Mueller V., Wallwiener D., et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Research 2007, 9(5):R74.
122. Fehm, Müller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Research and Treatment 2010, 124(2):403-412.
123. Pestrin, Bessi S., Galardi F., Truglia M., Biggeri A., Biagioni C., et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Research and Treatment 2009, 118(3):523-530.
124. Punnoose, Atwal S.K., Spoerke J.M., Savage H., Pandita A., Yeh R.F., et al. Molecular biomarker analyses using circulating tumor cells. PLoS ONE 2010, 5(9):e12517.
125. Riethdorf, Müller V., Zhang L., Rau T., Loibl S., Komor M., et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clinical Cancer Research 2010, 16(9):2634-2645.
126. Coumans, Ligthart S.T., Uhr J.W., Terstappen L.W. Challenges in the enumeration and phenotyping of CTC. Clinical Cancer Research 2012, 15(18(20)):5711-5718.
127. Rack B., Andergassen U., Janni W., Neugebauer J. CTCs in primary breast cancer (I). Recent Results in Cancer Research 2012, 195:179-185.
128. Zhao, Liu Y., Zhang Q., Li H., Zhang M., Ma W., et al. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Research and Treatment 2011, 130(3):809-816.
129. Zhang, Riethdorf S., Wu G., Wang T., Yang K., Peng G., et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clinical Cancer Research 2012, 18(20):5701-5710.
130. Wang, Yang X.Q., Yang S., Wang B.C., Feng M.H., Tu J.C., et al. A higher number of circulating tumor cells (CTC) in peripheral blood indicates poor prognosis in prostate cancer patients - a meta-analysis. Asian Pacific journal of cancer prevention 2011, 12(10):2629-2635.
131. Doyen, Alix-Panabières C., Hofman P., Parks S.K., Chamorey E., Naman H., et al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Critical Reviews in Oncology/Hematology 2012, 81(3):241-256.
132. Ma, Xiao Z.L., Liu L., Liu X.X., Nie W., Li P., et al. Meta-analysis of circulating tumor cells as a prognostic marker in lung cancer. Asian Pacific journal of cancer prevention 2012, 13(4):1137-1144.
133. Mego, De Giorgi U., Broglio K., Dawood S., Valero V., Andreopoulou E., et al. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British Journal of Cancer 2009, 101(11):1813-1816.
134. Davila, Amirkhosravi A., Coll E., Desai H., Robles L., Colon J., et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. Journal of Thrombosis and Haemostasis 2008, 6(9):1517-1524.
135. Berni-Lang, Aslan J.E., Tormoen G.W., Patel I.A., Bock P.E., Gruber A., et al. Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Physical Biology 2011, 8(1):01501.
136. Milsom, Anderson G.M., Weitz J.I., Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. Journal of Thrombosis and Haemostasis 2007, 5(12):2550-2552.
137. Milsom, Magnus N., Meehan B., Al-Nedawi K., Garnier D., Rak J. Tissue factor and cancer stem cells: is there a linkage?. Arteriosclerosis, Thrombosis, and Vascular Biology 2009, 29(12):2005-2014.
138. Milsom, Yu J.L., Mackman N., Micallef J., Anderson G.M., Guha A., et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumor initiation and angiogenesis. Cancer Research 2008, 68(24):10068-10076.
139. Tormoen, Haley K.M., Levine R.L., McCarty O.J. Do circulating tumor cells play a role in coagulation and thrombosis?. Frontiers in Oncology 2012, 2:115.
140. Tormoen, Cianchetti F.A., Bock P.E., McCarty O.J. Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Frontiers in Oncology 2012, 2:110.
141. Mani, Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
142. Hollier, Evans K., Mani S.A. The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. Journal of Mammary Gland Biology and Neoplasia 2009, 14:29-43.
143. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. European Journal of Cancer 2010, 46(7):1198-1203.
144. Chaffer C.L., Weinberg R.A. A perspective on cancer cell metastasis. Science 2011, 331(6024):1559-1564.
145. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
146. Al-Hajj, Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(7):3983-3988.
147. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23(43):7242-7282.
148. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994, 367(6464):645-648.
149. O'Brien, Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007, 445(7123):106-110.
150. Singh, Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., et al. Identification of human brain tumor initiating cells. Nature 2004, 432(7015):396-401.
151. Ricci-Vitiani, Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., et al. Identification and expansion of human colon cancer-initiating cells. Nature 2007, 445(7123):111-115.
152. Blazek, Foutch J.L., Maki G. Medulloblastoma cells that express CD133+ are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. International Journal of Radiation Oncology, Biology, Physics 2007, 67:1-5.
153. Yusra, Semba S., Yokozaki H. Biological significance of tumor buddin at the invasive front of human colorectal carcinoma cells. International Journal of Oncology 2012, 41(1):201-210.
154. Ishikawa, Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., et al. CHT-resistant human AML stem cells home to and engraft within bone-marrow endosteal region. Nature Biotechnology 2007, 25(11):1315-1321.
155. Liu, Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 2006, 5:67.
156. Li, Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al. Intrinsic resistance of tumorigenic breast cancer cells to CHT. Journal of the National Cancer Institute 2008, 100(9):672-679.
157. Ginestier, Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cancer Stem Cell 2007, 1(5):555-567.
158. Yu, Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131(6):1109-1123.
159. Fillmore C.M., Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive CHT. Breast Cancer Research 2008, 10(2):R25.
160. Phillips, McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute 2006, 98(24):1777-1785.
161. Mego, Mani S.A., Lee B.N., Li C., Evans K.W., Cohen E.N., et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. International Journal of Cancer 2012, 130(4):806-816.
162. Mego, Gao H., Lee B.N., Cohen E.N., Tin S., Giordano A., et al. Prognostic value of EMT-circulating tumor cells in metastatic breast cancer patients undergoing high-dose CHT with autologous hematopoietic stem cell transplantation. Journa of Cancer 2012, 3:369-380.
163. Li, Xu J.D., Wang W.J., Cao X.X., Chen Q., Tang F., et al. Twist1-mediated Adriamycin induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clinical Cancer Research 2009, 15:2657-2665.
164. -/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Human Pathology 2012, 43(3):364-373.
165. Giordano, Gao H., Anfossi S., Cohen E., Mego M., Lee B.N., et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular Cancer Therapeutics 2012, 11(11):2526-2534.
166. lo cancer stem cell phenotype. European Journal of Cancer 2011, 47(10):1527-1536.
167. Tanei, Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based CHT for breast cancer. Clinical Cancer Research 2009, 15(12):4234-4251.
168. Resetkova, Reis-Filho J.S., Jain R.K., Mehta R., Thorat M.A., Nakshatri H., et al. Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Research 2010, 123(1):97-108.
169. Gradilone, Naso G., Raimondi C., Cortesi E., Gandini O., Vincenzi B., et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of Oncology 2011, 22(1):86-92.
170. Jordan, Guzman M.L., Noble M. Cancer stem cells. New England Journal of Medicine 2006, 355(12):1253-1261.
171. Donnenberg V.S., Donnenberg A.D. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. Journal of Clinical Pharmacology 2005, 45(8):872-877.
172. Wang, Yang D., Lippman M.E. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Seminars in Oncology 2003, 30(5):133-142.
173. Gaforio, Serrano M.J., Sanchez-Rovira P., Sirvent A., Delgado-Rodriguez M., Campos M., et al. Detection of breast cancer cells in the peripheral blood is positively correlated wit estrogen-receptor status and predicts for poor prognosis. International Journal of Cancer 2003, 107(6):984-990.
174. Cristofanilli, Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New England Journal of Medicine 2004, 351:781-791.
175. Cristofanilli, Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of Clinical Oncology 2005, 23(7):1420-1430.
176. Bauernhofer, Zenahlik S., Hofmann G., Balic M., Resel M., Pirchmoser R., et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer. Oncology Reports 2005, 13(2):179-184.
177. Budd, Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clinical Cancer Research 2006, 12(21):6403-6409.
178. Hayes, Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overal survival. Clinical Cancer Research 2006, 12:4218-4224.
179. Xenidis, Perraki M., Kafousi M., Apostolaki S., Bolonaki I., Stathopoulou A., et al. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. Journal of Clinical Oncology 2006, 24:3756-3762.
180. Xenidis, Markos V., Apostolaki S., Perraki M., Pallis A., Sfakiotaki G., et al. Clinical relevance of circulating CK-19 mRNA-positve cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Annals of Oncology 2007, 18(10):1623-1631.
181. Ignatiadis, Xenidis N., Perraki M., Apostolaki S., Politaki E., Kafousi M., et al. Different prognostic value of cytokeratin-19 mRNA-positive circulating tumor cells according to estrogen receptor and HER2-status in early-stage breast cancer. Journal of Clinical Oncology 2007, 25(33):5194-5202.
182. Dawood, Broglio K., Valero V., Reuben J., Handy B., Islam R., et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer 2008, 113(9):2422-2430.
183. Igniatiadis, Kallergi G., Ntoulia M., Perraki M., Apostolaki S., Kafousi M., et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Cancer Research 2008, 14(9):2593-2600.
184. Nole, Munzone E., Zorzino L., Minchella I., Salvatici M., Botteri E., et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Annals of Oncology 2008, 19(5):891-897.
185. Pierga, Bidard F.C., Mathiot C., Brain E., Delaloge S., Giachetti S., et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant CHT in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research 2008, 14:7004-7010.
186. Yagata, Nakamura S., Toi M., Bando H., Ohno S., Kataoka A. Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional trial in Japan. International Journal of Clinical Oncology 2008, 13:252-256.
187. De Giorgi, Valero V., Rohren E., Mego M., Doyle G.V., Miller M.C., et al. Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of Oncology 2009, 21:33-39.
188. 18F-Fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. Journal of Clinical Oncology 2009, 27(20):3303-3311.
189. Mego, De Giorgi U., Hsu L., Ueno N.T., Valero V., Jackson S., et al. Circulating tumor cells in metastatic inflammatory breast cancer. Annals of Oncology 2009, 20(11):1824-1828.
190. Serrano, Sánchez-Rovira P., Delgado-Rodriguez M., Gaforio J.J. Detection of circulating tumor cells in the context of treatment: prognostic value in breast cancer. Cancer Biology and Therapy 2009, 8(8):671-675.
191. Tewes, Aktas B., Welt A., Mueller S., Hauch S., Kimmig R., et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Research and Treatment 2009, 115:581-590.
192. Xenidis, Ignatiadis M., Apostolaki S., Perraki M., Kalbakis K., Agelaki S., et al. Cytokeratin-19 mRNA-positve circulating tumor cells after adjuvant CHT in patients with early breast cancer. Journal of Clinical Oncology 2009, 27(13):2177-2184.
193. Bidard, Mathiot C., Delaloge S., Brain E., Giachetti S., de Cremoux P., et al. Single circulating tumor cell detection and overall survival in nonmetastic breast cancer. Annals of Oncology 2010, 21(4):729-733.
194. Botteri, Sandri M.T., Bagnardi V., Munzone E., Zorzino L., Rotmensz N., et al. Modeling the relationship between circulating tumor cells number and prognosis of metastatic breast cancer. Breast Cancer Research and Treatment 2010, 122:211-217.
195. 18F-FDG PET/CT findings and circulating tumor cells counts in the monitoring of systemic therapies for bone metastases from breast cancer. Journal of Nuclear Medicine 2010, 51(8):1213-1218.
196. Liu, Shields P.G., Warren R.D., Cohen P., Wilkinson M., Ottaviano Y.L., et al. Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. Journal of Clinical Oncology 2009, 27(31):5153-5159.
197. Aktas, Müller V., Tewes M., Zeitz J., Kasimir-Bauer S., Loehberg C.R., et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecologic Oncology 2011, 122(2):356-360.
198. Consoli, Grisanti S., Amoroso V., Almici C., Verardi R., Marini M., et al. Circulating tumor cells as predictors of prognosis in metastatic breast cancer: clinical application outside a clinical trial. Tumori 2011, 97(6):737-742.
199. Giuliano, Giordano A., Jackson S., Hess K.R., De Giorgi U., Mego M., et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research 2011, 13(3):R67.
200. Hartkopf, Wagner P., Wallwiener D., Fehm T., Rothmund R. Changing levels of circulating tumor cells in monitoring CHT response in patients with metastatic breast cancer. Anticancer Research 2011, 31(3):979-984.
201. Molloy, Bosma A.J., Baumbusch L.O., Synnestvedt M., Borgen E., Russnes H.G., et al. The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Research 2011, 14(13(3)):R61.
202. Sieuverts, Mostert B., Bolt-de Vries J., Peeters D., de Jongh F.E., Stouthard J.M., et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical Cancer Research 2011, 17(11):3600-3618.
203. Bidard, Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. Assesment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Research 2012, 14(1):R29. [Epub ahead of print].
204. De Giorgi, Mego M., Scarpi E., Giuliano M., Giordano A., Reuben J.M., et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clinical Breast Cancer 2012, 12(4):264-269.
205. Georgoulias, Bozionelou V., Agelaki S., Perraki M., Apostolaki S., Kallergi G., et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting CHT-resistant CK19 mRNA-positive circulating tumor cells: results of a randomized phase II study. Annals of Oncology 2012, 23(7):1744-1750.
206. Giordano, Giuliano M., De Laurentiis M., Arpino G., Jackson S., Handy B.C., et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of Oncology 2012, 23(5):1144-1150.
207. Hayashi, Nakamura S., Tokuda Y., Shimoda Y., Yagata H., Yoshida A. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International Journal of Clinical Oncology 2012, 17(2):96-104.
208. Hwang, Bae J.W., Lee H.Y., Kim H.Y. Circulating tumor cells detected by RT-PCR for CK-20 before surgery indicate worse prognostic impact in triple-negative and HER2 subtype breast cancer. Journal of Breast Cancer 2012, 15(1):34-42.
209. Lucci, Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncology 2012, 13(7):688-695.
210. Mathiesen, Borgen E., Renolen A., Løkkevik E., Nesland J.M., Anker G., et al. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research 2012, 14(14(4)):R117.
211. Payne, Wang F., Su N., Krell J., Zebrowski A., Yagüe E., et al. Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients. British Journal of Cancer 2012, 106(11):1790-1797.
212. Pierga, Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line CHT for metastatic breast cancer patients. Annals of Oncology 2012, 23(3):618-624.
213. Tjensvoll, Oltedal S., Heikkilä R., Kvaløy J.T., Gilje B., Reuben J.M., et al. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome. BMC Cancer 2012, 28(12):190.
214. Serrano, Rovira P.S., Martínez-Zubiaurre I., Rodriguez M.D., Fernández M., Lorente J.A. Dynamics of circulating tumor cells in early breast cancer under neoadjuvant therapy. Experimental and Therapeutic Medicine 2012, 4(1):43-48.
215. Cohen, Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008, 26(19):3213-3221.
216. Koyanagi, Bilchik A.J., Saha S., Turner R.R., Wiese D., McCarter M., et al. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clinical Cancer Research 2008, 14(22):7391-7396.
217. Tol, Koopman M., Miller M.C., Tibbe A., Cats A., Creemers G.J., et al. Circulating tumor cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with CHT and targeted agents. Annals of Oncology 2010, (5):1006-1012.
218. Cohen, Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology 2009, 20(7):1223-1229.
219. Iinuma, Watanabe T., Mimori K., Adachi M., Hayashi N., Tamura J., et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes'stage B and C colorectal cancer. Journal of Clinical Oncology 2011, 29(12):1547-1555.
220. Lu, Uen Y.H., Tsai H.L., Chuang S.C., Hou M.F., Wu D.C., et al. Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse. British Journal of Cancer 2011, 104(7):1178-1184.
221. Matsusaka, Suenaga M., Mishima Y., Kuniyoshi R., Takagi K., Terui Y., et al. Circulating tumor cells as a surrogate marker for determining response to CHT in Japanese patients with metastatic colorectal cancer. Cancer Sci 2011, 102(6):1188-1192.
222. Aggarwal, Meropol N.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Annals of Oncology 2012, (Oct 1). [Epub ahead of print].
223. Albuquerque, Kubisch I., Stölzel U., Ernst D., Boese-Landgraf J., Breier G., et al. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients. Journal of Translational Medicine 2012, 10(1):222. [Epub ahead of print].
224. Sastre, Maestro M.L., Gómez-España A., Rivera F., Valladares M., Massuti B., et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line CHT plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012, 17(7):947-955.
225. Sato, Hayashi N., Imamura Y., Tanaka Y., Kinoshita K., Kurashige J., et al. Usefulness of transcription-reverse transcription concerted reaction method for detecting circulatin tumor cells in patients with colorectal cancer. Annals of Surgical Oncology 2012, 19:2060-2065.
226. Shimada, Iinuma H., Akahane T., Horiuchi A., Watanabe T. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncology Reports 2012, 27(4):947-953.
227. Moreno, Miller M.C., Gross S., Allard W.J., Gomella L.G., Terstappen L.W. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 2005, 65(4):713-718.
228. Danila, Heller G., Gignac G.A., Gonzalez-Espinoza R., Anand A., Tanaka E., et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research 2007, 13(23):7053-7058.
229. De Bono, Scher H.I., Montgomery R.B., Parker C., Miller M.C., Tissing H., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 2008, 14(19):6302-6309.
230. Goodman, Fink L.M., Symanowski J.T., Wong B., Grobaski B., Pomerantz D., et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiology, Biomarkers and Prevention 2009, 18:1904-1913.
231. Okegawa, Nutahara K., Higashihara E. Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. Journal of Urology 2009, 181(3):1091-1097.
232. Olmos, Arkenau H.T., Ang J.E., Ledaki I., Attard G., Carden C.P., et al. Circulating tumor cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Annals of Oncology 2009, 20(1):27-33.
233. Resel Folkersma L., San José Manso L., Galante Romo I., Moreno Sierra J., Olivier Gómez C. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer. Urology 2012, October:1049-1057. pii: S0090-4295(12)01049-7 [Epub ahead of print]. 10.1016/j.urology.2012.09.001.
234. Chen, Jiang G.L., Fu X.L., Wang L.J., Qian H., Wu K.L., et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007, 56(1):105-114.
235. Yie, Lou B., Ye S.R., He X., Cao M., Xie K., et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009, 63(2):284-290.
236. Krebs, Sloane R., Priest L., Lancashire L., Hou J.M., Greystoke A., et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29(12):1556-1563.
237. Yoon, Kim Y.T., Jung K.C., Jeon Y.K., Kim B.H., Kim C.W. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 2011, 71(2):209-216.
238. Das, Riess J.W., Frankel P., Schwartz E., Bennis R., Hsieh H.B., et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012, 77(2):421-426.
239. Hiltermann, Pore M.M., van den Berg A., Timens W., Boezen H.M., Liesker J.J., et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Annals of Oncology 2012, 23(11):2937-2942.
240. Hou, Krebs M.G., Lancashire L., Sloane R., Backen A., Swain R.K., et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. Journal of Clinical Oncology 2012, 30(5):525-532.
241. Naito, Tanaka F., Ono A., Yoneda K., Takahashi T., Murakami H., et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. Journal of Thoracic Oncology 2012, 7(3):512-519.
242. Gradilone, Petracca A., Nicolazzo C., Gianni W., Cortesi E., Naso G., et al. Prognostic significance of surviving-expressing circulating tumor cells in T1G3 bladder cancer. BJU International 2010, 106(5):710-715.
243. Gazzaniga, Gradilone A., de Berardinis E., Busetto G.M., Raimondi C., Gandini O., et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Annals of Oncology 2012, (Feb 28). [Epub ahead of print].
244. Fan, Zhao Q., Chen J.J., Chen W.T., Pearl M.L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecologic Oncology 2009, 112(1):185-191.
245. Aktas, Kasimir-Bauer S., Heubner M., Kimmig R., Wimberger P. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based CHT. International Journal of Gynecological Cancer 2011, 21(5):822-830.
246. Poveda, Kaye S.B., McCormack R., Wang S., Parekh T., Ricci D., et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecologic Oncology 2011, 122(3):567-572.
247. Obermayr, Castillo-Tong D.C., Pils D., Speiser P., Braicu I., Van Gorp T., et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - a study of the OVCAD consortium. Gynecologic Oncology 2012, (Sep 24). pii: S0090-8258(12)00777-9 [Epub ahead of print]. 10.1016/j.ygyno.2012.09.021.